4.6 Article

Prevalence of anti-synthetase antibodies among systemic sclerosis patients

Journal

EUROPEAN JOURNAL OF INTERNAL MEDICINE
Volume 117, Issue -, Pages 98-102

Publisher

ELSEVIER
DOI: 10.1016/j.ejim.2023.07.010

Keywords

Systemic sclerosis; Anti synthetase antibodies; Interstitial lung disease; Myositis antibodies

Ask authors/readers for more resources

This study aimed to estimate the prevalence of Anti-ARS antibodies among patients with systemic sclerosis and evaluate their clinical associations and risk factors for interstitial lung disease. The results showed a 6% prevalence of Anti-ARS antibodies, which were associated with the development of ILD.
Background: we aimed to estimate the prevalence of Amino acyl-transfer ribonucleic acid synthetase antibodies (Anti-ARS); myositis specific antibodies, among patients with systemic sclerosis (SSc), to evaluate the clinical associations of anti-ARS antibodies in SSc patients and to identify risk factors for development of interstitial lung disease (ILD) in SSc. Methods: A prospective study of 71 systemic sclerosis patients in our rheumatology clinic in Israel. Sera were tested for myositis antibodies. Data on patients clinical and serological manifestations and treatment were collected and compared according to anti-ARS antibodies and ILD. Results: Prevalence of anti-ARS antibodies was 6% (4/71) with anti PL-7, anti- OJ and Jo-1 positivity. Anti Ro-52 was found in 27%, anti-PM/Scl 75, anti-PM/Scl 100 and anti-SRP in 6%, anti-Ku in 3%, anti-Mi-2 beta and antiMi-2 alfa in 4%, anti- NXP2 and anti-TIF1gamma in 1%. ILD complication was observed in 42% of patients and was associated with anti RNAP-III, anti Scl-70 and Anti-ARS antibodies. In multiple logistic regression, anti Scl70 was associated with 6-fold higher risk for ILD. Conclusion: Anti-ARS antibodies were observed in 6% of SSc patients. All of them had ILD. Due to the low prevalence of anti-ARS, this study could not describe clinical associations of anti-ARS antibodies in SSc patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available